| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 9,900 | $40 | $376.2K |
| J9271 | Injection, pembrolizumab, 1 mg | 4,700 | $40 | $202.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 460 | $110 | $48K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 610 | $80 | $45.7K |
| J0897 | Injection, denosumab, 1 mg | 2,460 | $20 | $44.3K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13,020 | $1 | $26K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 210 | $120 | $25.5K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,050 | $20 | $24.1K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 180 | $70 | $12.4K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 110 | $100 | $11.9K |